A phase III study of HS-410 either as an adjunct to BCG or a replacement for BCG altogether in patients with non-muscle invasive bladder cancer
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Vesigenurtucel-L (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 11 May 2017 Status changed from planning to withdrawn prior to enrolment, as reported in a Heat Biologics media release.
- 15 Aug 2016 According to Heat Biologics media release, the company anticipates to reported topline data from this study in the fourth quarter of 2016.
- 13 Aug 2015 New trial record